The Alliance for Children's Therapeutics (ACT) is a unique collaboration between one of the nation's top-five pediatric research institutions — Seattle Children's Research Institute — and Kineta Inc., and KPI Therapeutics, leading Seattle-based biotechnology firms.
ACT addresses a key problem: Big pharmaceutical companies can't justify spending millions of dollars to develop pediatric medications — the market is too small compared to medications for adults. What's more, the National Institutes of Health devotes only about 6% of its budget to pediatric research and that funding is shrinking. The result is that only a small fraction of today's medications were developed for — or tested in — children. Of the 55,000 clinical trials conducted between 2005 and 2010, only 9% were designed for children and teens younger than 18.
This leaves care teams on their own to figure out how to apply adult treatments to young patients. But children aren't small adults. They're more complicated, with developing minds and bodies that have unique needs, and are uniquely vulnerable to medication side effects. ACT is dedicated to creating medications for diseases that afflict children and teens.
We do this by uniting our strengths. Seattle Children's Research Institute makes discoveries that improve knowledge of childhood diseases and conditions and how to cure and better treat them. Kineta and KPI Therapeutics specialize in turning those discoveries into real-world treatments.
Our first project investigates a new drug candidate, called dalazatide, that could dramatically improve treatment for children and teens with lupus nephritis and other autoimmune diseases.